hotspot -WSS

hotspot

author：leisure time 2025-09-27 23:03:09 - browse：181

WASHINGTON — For those already felled by fumes from the Brazilian Blowout, it might be small consolation, but lawmakers are pushing ahead with a campaign for better oversight of the beauty business.

Despite its booming growth, the cosmetics industry in the US has been virtually unregulated. The Food, Drug, and Cosmetic Act, adopted in 1938, essentially allowed personal care product companies to self-police.

But rising public concern over bad reactions to makeup, hair dyes, and fragrances, as well as evidence of long-term health risks from some of their chemical contents, has led lawmakers to try to toughen the regulatory framework for the $60 billion enhancement industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CVS is on a mission to consolidate health care. Will it work?

hotspot

WSS

STAT readers on older presidents, polypills, Medicare, and more

Head of FDA's diagnostics center, who led through Covid, retires

To bolster infectious disease surveillance, genomics powerhouses team up

Alabama hospital puts IVF treatments on hold

Dana Farber says 6 studies to be retracted and 31 corrected

Antivenom research: Lessons from HIV applied in search for universal antidote

explore

hotspot

hotspot

The high cost of giving birth even with insurance

The inclusion problem at the heart of rehabilitation research

Medical leaders decry Supreme Court decision on affirmative action

STAT readers on older presidents, polypills, Medicare, and more

Apple is now the first public company to be valued at $3 trillion

FDA endorses new sterilization method for medical devices

Hepatitis C has a cure — but many Americans still lack access to it

Medicare inequities exacerbate Puerto Rico’s health disparities

Hepatitis C has a cure — but many Americans still lack access to it

Ed Silverman on new gene therapies, biosimilars, coffee, and more

hotspot

Future doctors need a strong humanities education

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

To bolster infectious disease surveillance, genomics powerhouses team up

FDA sets aggressive timeline for overhauling inspection procedures

With competition flaring, obesity drug hits goal in liver disease study

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

knowledge

hotspot

entertainment